Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone

医学 蛋白尿 肾脏疾病 2型糖尿病 内科学 全国健康与营养检查调查 糖尿病 危险系数 入射(几何) 肾功能 人口 冲程(发动机) 心肌梗塞 比例危险模型 置信区间 内分泌学 环境卫生 机械工程 物理 工程类 光学
作者
Rajiv Agarwal,Bertram Pitt,Peter Rossing,Stefan D. Anker,Gerasimos Filippatos,Luís M. Ruilope,Csaba P. Kövesdy,Katherine R. Tuttle,Muthiah Vaduganathan,Christoph Wanner,Sameer Bansilal,Martin Gebel,Amer Joseph,Robert Lawatscheck,George L. Bakris
出处
期刊:JAMA Cardiology [American Medical Association]
卷期号:8 (8): 732-732 被引量:25
标识
DOI:10.1001/jamacardio.2023.1505
摘要

Importance It is currently unclear whether chronic kidney disease (CKD)–associated cardiovascular risk in type 2 diabetes (T2D) is modifiable. Objective To examine whether cardiovascular risk can be modified with finerenone in patients with T2D and CKD. Design, Setting, and Participants Incidence rates from Finerenone in Chronic Kidney Disease and Type 2 Diabetes: Combined FIDELIO-DKD and FIGARO-DKD Trial Programme Analysis (FIDELITY), a pooled analysis of 2 phase 3 trials (including patients with CKD and T2D randomly assigned to receive finerenone or placebo) were combined with National Health and Nutrition Examination Survey data to simulate the number of composite cardiovascular events that may be prevented per year with finerenone at a population level. Data were analyzed over 4 years of consecutive National Health and Nutrition Examination Survey data cycles (2015-2016 and 2017-2018). Main Outcomes and Measures Incidence rates of cardiovascular events (composite of cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, or hospitalization for heart failure) were estimated over a median of 3.0 years by estimated glomerular filtration rate (eGFR) and albuminuria categories. The outcome was analyzed using Cox proportional hazards models stratified by study, region, eGFR and albuminuria categories at screening, and cardiovascular disease history. Results This subanalysis included a total of 13 026 participants (mean [SD] age, 64.8 [9.5] years; 9088 male [69.8%]). Lower eGFR and higher albuminuria were associated with higher incidences of cardiovascular events. For recipients in the placebo group with an eGFR of 90 or greater, incidence rates per 100 patient-years were 2.38 (95% CI, 1.03-4.29) in those with a urine albumin to creatinine ratio (UACR) less than 300 mg/g and 3.78 (95% CI, 2.91-4.75) in those with UACR of 300 mg/g or greater. In those with eGFR less than 30, incidence rates increased to 6.54 (95% CI, 4.19-9.40) vs 8.74 (95% CI, 6.78-10.93), respectively. In both continuous and categorical models, finerenone was associated with a reduction in composite cardiovascular risk (hazard ratio, 0.86; 95% CI, 0.78-0.95; P = .002) irrespective of eGFR and UACR ( P value for interaction = .66). In 6.4 million treatment-eligible individuals (95% CI, 5.4-7.4 million), 1 year of finerenone treatment was simulated to prevent 38 359 cardiovascular events (95% CI, 31 741-44 852), including approximately 14 000 hospitalizations for heart failure, with 66% (25 357 of 38 360) prevented in patients with eGFR of 60 or greater. Conclusions and Relevance Results of this subanalysis of the FIDELITY analysis suggest that CKD-associated composite cardiovascular risk may be modifiable with finerenone treatment in patients with T2D, those with eGFR of 25 or higher, and those with UACR of 30 mg/g or greater. UACR screening to identify patients with T2D and albuminuria with eGFR of 60 or greater may provide significant opportunities for population benefits.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
酷炫若枫发布了新的文献求助10
刚刚
numagok完成签到,获得积分0
1秒前
科研通AI6.3的应助被挽风采纳,获得10
1秒前
英姑的应助被tongluobing采纳,获得50
2秒前
cdercder的应助被Sky我的小清新采纳,获得10
3秒前
春风暮雪发布了新的文献求助30
5秒前
ding的应助被当康康采纳,获得10
5秒前
PAL81048完成签到 ,获得积分10
6秒前
xing完成签到,获得积分10
6秒前
shenkekeshen完成签到 ,获得积分10
6秒前
6秒前
shenkekeshen完成签到 ,获得积分10
7秒前
shenkekeshen完成签到 ,获得积分10
8秒前
干净的向秋完成签到 ,获得积分10
8秒前
酷炫若枫完成签到,获得积分10
9秒前
FX完成签到,获得积分10
9秒前
东方白完成签到,获得积分10
9秒前
小灰机完成签到,获得积分10
10秒前
10秒前
12秒前
sll完成签到,获得积分10
12秒前
上官若男的应助被曹凯玥采纳,获得10
13秒前
13秒前
SixFan完成签到,获得积分10
13秒前
14秒前
xh完成签到,获得积分10
15秒前
ruin发布了新的文献求助10
16秒前
丘比特的应助被cxq采纳,获得10
17秒前
陈陈陈完成签到,获得积分10
18秒前
David发布了新的文献求助10
18秒前
18秒前
卡西莫多完成签到,获得积分10
18秒前
当康康发布了新的文献求助10
19秒前
翻斗花园胡英俊完成签到,获得积分10
19秒前
九月发布了新的文献求助10
20秒前
MAXDONE完成签到,获得积分10
22秒前
德天完成签到,获得积分10
22秒前
瘦瘦安卉发布了新的文献求助10
23秒前
SciGPT的应助被小邹采纳,获得10
23秒前
赘婿的应助被冷酷的问寒采纳,获得10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191414
求助须知:如何正确求助?哪些是违规求助? 9578277
关于积分的说明 21857909
捐赠科研通 7790787
什么是DOI,文献DOI怎么找? 3436640
关于科研通互助平台的介绍 2560362
邀请新用户注册赠送积分活动 2483366